Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

NCT04133337 | Unknown Phase 1

• 1 other identifier: HR-SHR-NSCLC201906
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.

Conditions

Lung Diseases; Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Non-small-cell Lung Cancer

Keywords

Apatinib; SHR-1210; NSCLC; neoadjuvant

Outcome Measures

Primary Outcomes (1)

• Major pathologic response rate(MPR)(<10% viable tumor cells)

  To assess the major pathologic response rate (\<10% viable tumor cells) in patients receiving Apatinib Combined With SHR-1210 Injection.

  At time of surgery

Secondary Outcomes (3)

• Disease Control Rate (DCR)

  up to 2 years

• Overall response rate (ORR)

  up to 2 years

• Disease-free survival (DFS)

  up to 2 years

Other Outcomes (2)

• Incidence of irAEs

  up to 2 years

• Incidence of SAEs

  up to 2 years

Study Arms (1)

Apatinib Combined With SHR-1210 Injection

EXPERIMENTAL

* Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery. * Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion. * Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose.

Drug: Apatinib; Drug: SHR-1210

Interventions

Apatinib DRUG

Apatinib Mesylate Tablets

Also known as: AiTan, H20140103

Apatinib Combined With SHR-1210 Injection

SHR-1210 DRUG

Camrelizumab for Injection

Also known as: Camrelizumab, Karuilizhu Dankang, S20190027

Apatinib Combined With SHR-1210 Injection

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Age: 18 years old to 75 years old, male or female;
• \. Initial treatment of patients with IB-IIIA non-small cell lung cancer who are expected to be surgically resected;
• \. Histopathologically confirmed non-small cell lung cancer with measurable tumor lesions (spiral CT scan≥10mm, meeting RECIST 1.1 criteria);
• \. ECOG PS: 0-1 points
• \. The function of important organs meets the following requirements (no blood components and cell growth factors are allowed for 2 weeks before the start of study): Absolute neutrophil count (ANC)≥1.5×10 E+9/L; platelets≥100×10E+9/L / L; hemoglobin ≥9g/dL; serum albumin(ALB)≥2.8g/dL; a total bilirubin (TBil) of≤1.5 ULN, ALT and AST≤2.5 ULN, in case of liver metastasis, ALT and AST≤5 ULN; creatinine clearance rate≥ 50mL/min(Cockcroft-Gault);thyroid function is normal.
• \. Estimated survival time≥3 months;
• \. Female subjects with fertility should undergo a urine or serum pregnancy test within 72 hours prior to the first study drug administration and are shown to be negative ,and willing to be 3 months after the last dose of SHR-1210 injection during the trial period. The effective method was used for contraception (from the control group to 180 days after the last administration). For male subjects whose partners are women of childbearing age, effective methods should be used during the test period and within 3 months after the last administration of SHR-1210 injection (control group to 180 days after the last administration);
• \. Patients were voluntarily enrolled in the study and signed an informed consent form (ICF) with good adherence and follow-up.

You may not qualify if:

• \. The patient has any active autoimmune disease or a history of autoimmune disease;
• The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose\>10 mg / day of prednisone or other therapeutic hormones);
• Interstitial pneumonia ;
• Severe allergic reactions to other monoclonal antibodies ;
• Suffering from high blood pressure and not being well controlled by antihypertensive medication (systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg) ;
• Have clinical symptoms or disease that are not well controlled ;
• Abnormal coagulation function (INR\>2.0, PT\>16s), bleeding tendency or receiving thrombolysis or anticoagulant therapy, allowing prophylactic use of low-dose aspirin, low molecular weight heparin;
• There was significant coughing blood in the first 2 months before enrollment, or daily hemoptysis amounted to 2.5ml or more;
• Significant clinically significant bleeding symptoms or a clear tendency to hemorrhage during the first 3 months of randomization;
• Urinary routine suggests urinary protein≥ ++ and confirmed 24-hour urine protein\> 1.0 g ;
• The patient has active infection, unexplained fever within 3 days before administration, ≥38.5 °C, or baseline white blood cell count\>15×109/L;
• The patient has previously received other PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1;

Sponsors & Collaborators

• Sichuan Cancer Hospital and Research Institute: lead
• Jiangsu HengRui Medicine Co., Ltd.: collaborator

Study Sites (1)

Sichuan Cancer Hospital

Chengdu, Sichuan, 610041, China

Location

MeSH Terms

Conditions

Lung Diseases; Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Carcinoma, Non-Small-Cell Lung

Interventions

apatinib; camrelizumab

Condition Hierarchy (Ancestors)

Neoplasms by Site; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms

Study Officials

• Juan Li, MD

  Sichuan Cancer Hospital and Research Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Juan Li, MD

CONTACT

+8613880276636; dr.lijuan@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: October 17, 2019
• First Posted: October 21, 2019
• Study Start: November 1, 2019
• Primary Completion: June 1, 2020
• Study Completion: June 1, 2021
• Last Updated: October 21, 2019

Record last verified: 2019-10

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)